Nebraska Innovation Campus (NIC) has announced a new partner. Dan Duncan, NIC’s executive director, said Celerion will move into this space on the campus in February of 2020.
 
Celerion has been conducting clinical research studies for over 50 years in Lincoln for pharmaceutical and biotechnology companies around the world, for investigational medicines currently in research and development, to treat a wide variety of illnesses and conditions. 
 
Celerion will be located on the first level of the Rise Building, NIC’s newest building. An open house will be hosted at the Rise Building in March. This event will provide Celerion staff the opportunity to learn about ways to partner with faculty and students, and for visitors to learn more about pharmaceutical research opportunities at Celerion and the drug development process.
 
“Celerion is a great long-term fit for NIC,” said Mr. Duncan. “Their clinical research expertise will be invaluable as the Nebraska Food for Health Center continues to develop and companies in the Biotech Connector mature.”
 
“Celerion is pleased to announce NIC as the location for our expansion,” said Phil Bach, vice president, global clinical research, Celerion. “We’re excited to take this next step to further our clients’ goals for drug development. This space will allow us to partner with top-notch students, faculty, and entrepreneurs at NIC and collaborate at the forefront of the biotechnology hub in Nebraska.”
 
The new location at NIC demonstrates Celerion’s commitment to innovation and excellence in clinical research, Bach said.
 
“We are committed to scientific excellence that gives our clients the confidence to make fast, accurate decisions about their drug development path,” said Mr. Bach. “Establishing a partnership at NIC will allow us to provide new service avenues as clients look to bring their drugs to market.”